Testing ACT500 for liver disease (MASLD) safety and effects
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a new medication called ACT500 for people with fatty liver disease (MASLD). The goal is to see if it is safe and how the body processes it. You may be able to join if you have at least 10% liver fat, some liver scarring or damage, and certain metabolic risk factors like being overweight or having prediabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have fatty liver disease with at least 10% liver fat measured by a special MRI scan.
- You have some liver scarring (between mild and moderate) or a recent liver biopsy showing stage F2 or F3 fibrosis.
- Your blood tests show elevated liver enzymes (ALT level between 2 and 5 times the upper limit of normal).
- You have at least one metabolic risk factor, such as being overweight, having prediabetes or type 2 diabetes, high triglycerides, low 'good' cholesterol, or high blood pressure.
- You have not had recent weight loss surgery, heavy alcohol use, or used other medications for this condition in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study tests a new drug called ACT500 in people who have both fatty liver disease and chronic hepatitis B infection. The goal is to understand how safe the drug is and how well it works to improve liver health.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
Hear when a new Metabolic Dysfunction-associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.